Kamada (KMDA) Asset Utilization Ratio (2013 - 2026)
Kamada (KMDA) posted quarterly Asset Utilization Ratio of 117.87 for Q1 2026, up 3.4% year-on-year from 113.99 in Q1 2025, and down 0.76% on a QoQ basis from 118.77 in Q4 2025.
Kamada (KMDA) Asset Utilization Ratio (2013 - 2026) Analysis & Trends
Kamada (KMDA) has reported Asset Utilization Ratio for 11 consecutive years, with 117.87 the latest figure, recorded in Q1 2026.
- Quarterly Asset Utilization Ratio rose 3.4% year-over-year to 117.87 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 117.87 (up 3.4% YoY) and the FY2025 annual result came in at 0.48, up 52943.48% from the prior year.
- Asset Utilization Ratio slipped to 117.87 in Q1 2026 per KMDA's latest filing, from 118.77 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for KMDA reached as high as 199.66 in Q2 2023 and fell as low as 0.0 in Q1 2024.
- A 5-year average of 91.5 and a median of 117.74 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio sank 100.0% — and 2025, when it soared 13539603.37%.
- Year by year, Asset Utilization Ratio stood at 100.66 in 2022, then plunged by 99.91% to 0.09 in 2023, then surged by 132066.19% to 117.74 in 2024, then grew by 0.87% to 118.77 in 2025, then retreated by 0.76% to 117.87 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 117.87, 118.77, and 120.43 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 117.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117.87 |
| Dec 31, 2025 | 118.77 |
| Sep 30, 2025 | 120.43 |
| Jun 30, 2025 | 120.76 |
| Mar 31, 2025 | 113.99 |
| Dec 31, 2024 | 117.74 |
| Sep 30, 2024 | 121.29 |
| Jun 30, 2024 | 122.68 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.09 |
| Sep 30, 2023 | 0.18 |
| Jun 30, 2023 | 199.66 |
| Mar 31, 2023 | 197.12 |
| Dec 31, 2022 | 100.66 |
| Sep 30, 2022 | 103.56 |
| Jun 30, 2022 | 0.35 |
| Mar 31, 2022 | 0.34 |
| Dec 31, 2021 | 0.39 |
| Sep 30, 2021 | 0.48 |
| Jun 30, 2021 | 0.54 |